(NASDAQ: IMRX) Immuneering's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 12.05%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 32.95%.
Immuneering's earnings in 2026 is -$66,503,915.On average, 9 Wall Street analysts forecast IMRX's earnings for 2026 to be -$75,306,597, with the lowest IMRX earnings forecast at -$82,508,259, and the highest IMRX earnings forecast at -$70,041,352. On average, 9 Wall Street analysts forecast IMRX's earnings for 2027 to be -$76,627,765, with the lowest IMRX earnings forecast at -$96,471,196, and the highest IMRX earnings forecast at -$19,720,381.
In 2028, IMRX is forecast to generate -$115,161,842 in earnings, with the lowest earnings forecast at -$118,684,958 and the highest earnings forecast at -$105,402,035.